CD123 ADC

CD123 ADC refers to a class of antibody-drug conjugates (ADCs) designed to target the interleukin-3 receptor alpha chain (CD123), a cell surface antigen frequently overexpressed in various hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). These therapeutic agents consist of a CD123-specific monoclonal antibody covalently linked to a cytotoxic payload. The mechanism of action involves the antibody binding to CD123 on the surface of malignant cells, followed by internalization of the ADC and subsequent intracellular release of the payload, which induces cell death. Research by companies such as Eigen Therapeutics focuses on enhancing the efficacy of CD123 ADCs through priming strategies that selectively upregulate CD123 expression on cancer cells, thereby widening the therapeutic window and overcoming antigen heterogeneity.

Other names

anti-CD123 ADCanti-CD-123 ADCanti-CD 123 ADCCD123-directed antibody-drug conjugateCD-123-directed antibody-drug conjugateCD 123-directed antibody-drug conjugate